India Medical Tourism — World-Class Treatment at Fraction of EU Costs
Facilitating European, African, and Middle Eastern patients' access to India's world-class hospitals for elective, specialist, and complex medical procedures.
Medical TourismIndia HospitalsJCI AccreditedCost-Effective TreatmentNABHPatient Facilitation
$9B+
India medical tourism revenue (2024)
800,000+
Medical tourists to India (annual)
70–80%
Cost saving vs EU private treatment
30+
India JCI-accredited hospitals
700+
India NABH-accredited hospitals
10–20% package
Facilitator commission range
Quick Facts — Medical Tourism
◆Commission: 10–20% of treatment package value
◆Hospitals: JCI/NABH-accredited across major Indian cities
India's leading hospitals — Apollo, Fortis, Medanta, Narayana Health, Max Healthcare — offer NABH and JCI-accredited care at 20–30% of comparable European private treatment costs. Waiting lists in European public health systems and high private treatment costs are driving a growing flow of medical tourists to India. We act as a trusted facilitator: coordinating hospital introductions, managing consultation logistics, and supporting visa and travel — earning a transparent commission from empanelled hospitals.
Global Bilateral Reach
🌍
Africa
🌎
Americas
🌏
Asia-Pacific
🇪🇺
Europe
🌐
Middle East
🏔️
Central Asia
Commission Structure
We earn a facilitator commission of 10–20% of the treatment package value from the empanelled hospital. No fee is charged to the patient at any stage. Our hospital empanelment is based on accreditation, outcomes, and patient experience — not commission rate.
Deal Size
Commission Rate
Indicative Earning
Diagnostic / minor procedure
15–20%
€2k–€8k package
Major surgery (cardiac, orthopaedic, cancer)
10–15%
€8k–€30k package
Complex / transplant cases
10–12%
€30k–€80k package
UKGermanyFranceNigeriaKenyaUAEBangladeshAfghanistanCIS countries
Commission Protection
All commissions confirmed in writing via NCNDA + Commission Agency Agreement before any introduction. Five-year non-circumvention protection. Payment typically net 10 business days from trigger event.
Subject-matter expertise + global network + documented deal process. The only intermediary model that works across borders.
01
Hospital & Specialist Identification
We identify the most appropriate hospital and specialist for the patient's specific diagnosis and treatment requirement — considering accreditation, specialist experience, outcomes data, and cost.
02
Medical Record Review Coordination
We facilitate the secure transmission of the patient's medical records to the Indian specialist for remote review and a preliminary opinion — before any travel commitment is made.
03
Treatment Package & Cost Estimate
We obtain a detailed treatment package and cost estimate from the hospital, covering surgery, anaesthesia, hospital stay, post-operative care, and follow-up — enabling transparent budgeting.
04
Visa & Travel Coordination
We assist with Indian Medical Visa (e-MV) application guidance, airport transfers, accommodation near the treatment facility, and interpreter services where needed.
05
Post-Treatment Follow-Up
We facilitate the patient's handover to their home-country physician with complete discharge summaries, imaging, and treatment records — and coordinate telemedicine follow-up with the Indian specialist.
Full Bilateral Scope
Everything we can facilitate
A comprehensive scope of facilitation activity within this vertical — from first introduction through to repeat order management and multi-year supply agreements.
International patients from EU, Africa, Middle East, CIS
Indian JCI/NABH-accredited hospitals and specialist centres
Indian medical institutions seeking international patient partnerships
Overseas facilitators, insurance companies, corporate health programmes
Distribution Channel Development
We actively develop distribution channels via targeted prospecting with product samples, pilot shipments, and trial orders. Every new buyer relationship begins with a qualification call, followed by a documented sample or pilot order to prove commercial viability before any long-term commitment is made. This is the most effective route to sustainable bilateral volume.
Sector Intelligence
Historical Trends · Future Outlook · FTA Impact
Subject-matter intelligence underpinning our advisory and deal origination in this vertical. Updated annually by Vinod Kumar Jain (India-side) and Amit Jain (EU-side).
Historical Context
How This Sector Evolved
◆India's medical tourism sector emerged formally in the early 2000s — hospitals like Apollo, Fortis, and Wockhardt investing in international patient services divisions after recognising that their quality and cost combination was genuinely world-competitive.
◆The "pharmacy of the world" narrative extended naturally to "hospital of the world" — international patients from Africa, MENA, Bangladesh, and Central Asia initially, then progressively from UK, Germany, and France as waiting lists lengthened.
◆JCI (Joint Commission International) accreditation became the credential that unlocked European patient confidence — demonstrating that Indian hospitals met the same quality standards as accredited US and European facilities.
◆Medical visa (e-Medical Visa) simplification by India's Ministry of Health from 2015 reduced administrative friction — enabling same-day visa issuance for most nationalities and supporting Indian hospitals' international patient growth targets.
◆COVID-19 temporarily collapsed medical tourism flows (2020–2021) but accelerated telemedicine consultation infrastructure — Indian hospitals now conducting pre-travel remote consultations that convert hesitant international patients more effectively than brochures ever did.
Future Outlook 2025–2030
Where This Sector Is Heading
▶EU healthcare system strain: ageing populations, underfunded public health budgets, and growing elective procedure waiting lists (18–36 months for hip/knee replacement in many EU member states) creating structural demand for international medical options.
▶Insurance coverage expansion: EU supplemental health insurance products beginning to cover international medical tourism at accredited facilities — converting medical tourism from an out-of-pocket luxury to an insurance-covered option for middle-income EU patients.
▶Wellness and prevention tourism: beyond curative treatment, Indian facilities offering Ayurvedic wellness, yoga-based health management, and integrative medicine programmes that EU consumers increasingly seek — a premium, high-margin adjacent category.
▶Teleconsultation and hybrid care: Indian specialists conducting post-treatment follow-up via telemedicine — reducing the "stranded after return" anxiety that deters some EU patients, and enabling Indian hospitals to manage longer-term patient relationships.
▶Regenerative and precision medicine: Indian hospitals investing in stem cell therapy, CAR-T cell therapy, and personalised genomics — categories where EU access is either unavailable or prohibitively expensive, creating a new high-value patient segment.
📊
India–EU FTA Impact
Low Impact
Medical tourism facilitation is not directly governed by trade agreements — it is primarily driven by quality and cost differentials, bilateral insurance frameworks, and patient confidence. The FTA's indirect impact comes through the Mode 4 provisions that could enable Indian medical professionals to provide temporary services in EU (telehealth consultations, visiting specialist clinics) — and through the general improvement in India–EU bilateral relationships that increases European familiarity and trust with Indian institutions. A deeper bilateral relationship also creates the conditions for health sector cooperation agreements that could eventually include mutual recognition of certain medical qualifications and cross-referral protocols.
Every trade mandate carries risk. The following are the most common risks in this vertical — and exactly how Global Nexus structures deals to address each one.
⚠ Risk
Post-Treatment Complication — Liability Gap
EU patient experiences post-treatment complication in India — unclear liability allocation between facilitator, hospital, and treating physician.
✓ Mitigation
Medical tourism mandate includes signed Medical Services Agreement between patient and hospital (not Global Nexus) defining liability, complaint procedure, and applicable law. Global Nexus acts as facilitation intermediary — never as medical service provider.
⚠ Risk
Insurance Non-Coverage for Treatment Abroad
EU patient proceeds with India treatment assuming EU health insurance covers it — insurer refuses reimbursement, patient faces full cost.
✓ Mitigation
Insurance pre-authorisation confirmed in writing from EU insurer before treatment booking. Where insurance coverage is unavailable: treatment cost and payment plan confirmed with patient in advance.
⚠ Risk
Hospital Empanelment Failure
Medical tourism facilitator introduces patient to non-JCI/NABH hospital — quality below EU patient expectations, reputational damage.
✓ Mitigation
Global Nexus empanels only JCI-accredited or NABH-accredited hospitals. All hospitals subject to annual empanelment review. Hospital track record with international patients specifically verified.
Practitioner Intelligence
Tips & Insights from the Field
Drawn from Vinod Kumar Jain's 30+ years of India-side manufacturing relationships and Amit Jain's EU-side buyer and regulatory experience. These are the insights that differentiate deals that close from those that don't.
European health consumers understand JCI accreditation as equivalent to their home country hospital standards. JCI-accredited Indian hospitals (Apollo, Fortis, Manipal, Max, Narayana) can be presented to EU patients with full quality credibility. Non-JCI hospitals — regardless of actual quality — face a trust barrier with EU patients that is very difficult to overcome.
💡
Cost comparison is not just sticker price
The total EU patient cost comparison must include: treatment cost + flights + accommodation + insurance + recovery time (vs. waiting list in EU public system). Indian total cost including all above is typically 30-60% below equivalent EU private treatment — and 6-12 months faster than EU public system waiting lists. Present the full comparison, not just procedure cost.
💡
Oncology, orthopaedics, and cardiac are the three highest-volume EU categories
EU patients seeking India treatment are concentrated in: oncology (cancer treatment — 35%), orthopaedics (hip/knee replacement — 25%), and cardiac surgery (20%). These three categories account for 80% of medical tourism volume from EU to India. Build hospital empanelment around depth in these three specialisations rather than breadth across 20.
Ready to discuss a deal in this sector?
Porto, Portugal · +91 98881 47147 Panchkula, India · +91 98881 47147
Answers drawn from twenty-plus years of bilateral trade and advisory experience across this vertical.
We only work with hospitals holding active JCI (Joint Commission International) or NABH accreditation — the Indian equivalent of European hospital quality standards. We provide accreditation documentation to patients upfront.
Cost estimates are indicative pending the treating specialist's review of medical records and any additional investigations required on arrival. We advise patients to treat estimates as a guide and budget a 10–15% contingency.
JCI-accredited hospitals carry comprehensive professional indemnity insurance. In the event of complications, the treating hospital's risk management and patient relations team handle the process. We provide communication support throughout.
Yes. We coordinate accommodation and local support for accompanying family members and advise on companion visa requirements where applicable.
Yes, for therapeutic Ayurvedic treatment (panchakarma, chronic disease management) at accredited Ayurvedic hospitals. We do not facilitate basic wellness retreats under this vertical.
Have a question not answered here? Write to us directly — we respond to every enquiry personally within one working day.